Eisai's Halaven Faces Another Reimbursement Roadblock In Germany
Executive Summary
Eisai's cancer drug Halaven has suffered another reimbursement setback in Europe, with Germany's health technology appraisal body IQWiG slapping its "no additional benefit" rating on the product for use in patients with advanced liposarcoma.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.